# PleoPharma Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-withdrawal-syndrome-treatment-phase-3-trial/ > **Published:** 2026-06-19T12:22:42-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:51:35-04:00 > **Clinical Summary:** Explore the latest on cannabis withdrawal syndrome treatment with PleoPharma's Phase 3 trial of PP-01, a novel medication for cannabis use disorder. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchMental HealthSafetyDosingAnxietyNeurologyIndustry Why This Matters Clinicians treating patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) now have a potential therapeutic option in development, as PP-01 represents the first pharmacological agent specifically designed to address withdrawal symptoms that often impede treatment engagement and recovery. Cannabis withdrawal symptoms such as irritability, sleep disturbance, and anxiety are recognized barriers to abstinence, and an effective medication could improve treatment outcomes and retention rates in this patient population. This Phase 3 trial outcome will provide evidence on whether pharmacological intervention can reduce the medical and psychiatric morbidity associated with [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/), informing clinical practice guidelines and expanding the limited treatment armamentarium for this increasingly prevalent condition. Clinical Summary PleoPharma has initiated a pivotal Phase 3 trial for PP-01, a novel once-daily oral medication designed to treat cannabis withdrawal symptoms in patients with [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) disorder. This advancement follows earlier-phase data supporting the drug’s efficacy and safety profile and represents a critical step toward potential FDA approval and market availability. Cannabis withdrawal syndrome, characterized by irritability, sleep disturbance, anxiety, and mood changes, can significantly impede quit attempts and prolong abstinence periods, yet currently lacks FDA-approved pharmacological treatments. Successful completion of this Phase 3 trial could provide clinicians with the first evidence-based pharmaceutical option to manage withdrawal symptoms and improve treatment outcomes in patients seeking to reduce or discontinue [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/). For patients struggling with [cannabis dependence](https://cedclinic.com/ptsd-cannabis-dependence-veterans-social-support/), an approved medication would offer a meaningful alternative to behavioral interventions alone and could substantially increase treatment engagement and success rates in primary care and [addiction medicine](https://cedclinic.com/cognitive-flexibility-alcohol-cocaine-misuse-effects/) settings. Dr. Caplan’s Take “We’re at an early stage with PP-01, and while a Phase 3 trial represents meaningful progress, we need to see the complete efficacy and safety data before we know whether this will actually change clinical practice for cannabis withdrawal. The early signals here are worth watching, but the bar for any new pharmaceutical agent in this space is appropriately high.” Clinical Perspective 💊 The initiation of a Phase 3 trial for PP-01 as a treatment for cannabis withdrawal represents a potentially significant development for a growing clinical population, as [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) and withdrawal syndromes have become increasingly prevalent yet remain therapeutically underserved. While the announcement reflects progress in pharmacological management, clinicians should note that the trial’s design, patient population, and comparison arms remain incompletely characterized in this preliminary report, making it premature to draw conclusions about efficacy or clinical utility. Current evidence suggests that behavioral interventions remain the first-line approach for cannabis withdrawal, which is typically self-limited though uncomfortable, and any new pharmacotherapy would need to demonstrate clear benefits over standard supportive care to justify adoption in practice. As this trial progresses, healthcare providers caring for patients with [cannabis use disorder](https://cedclinic.com/sex-differences-cannabis-stress-reactivity-oxytocin/) should maintain awareness of emerging treatment options while continuing to emphasize psychosocial interventions and setting realistic expectations, recognizing that severe withdrawal is less 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-related-research/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20PleoPharma%2C%20Inc.%20Announces%20First%20Patient%20Dosed%20in%20Pivotal%20Phase%203%20Clinical%20...%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59684)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59684)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20PleoPharma%2C%20Inc.%20Announces%20First%20Patient%20Dosed%20in%20Pivotal%20Phase%203%20Clinical%20...%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59684)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [What’s in My Weed?](https://cedclinic.com/whats-in-my-weed/) - [PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …](https://cedclinic.com/pleopharma-inc-announces-first-patient-dosed-in-pivotal-phase-3-clinical-trial-of-pp-01/) - [PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …](https://cedclinic.com/pleopharma-inc-announces-first-patient-dosed-in-pivotal-phase-3-clinical-trial-of-pp-01/) 📰 Source: [https://firstwordpharma.com/story/7632137](https://firstwordpharma.com/story/7632137) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [PleoPharma, Inc. Announces First Patient Dosed in Pivotal Phase 3 Clinical Trial of PP-01 …](https://cedclinic.com/pleopharma-inc-announces-first-patient-dosed-in-pivotal-phase-3-clinical-trial-of-pp-01/) Detailed coverage of PleoPharma’s Phase 3 clinical trial for PP-01 targeting cannabis withdrawal symptoms. [Read More](https://cedclinic.com/pleopharma-inc-announces-first-patient-dosed-in-pivotal-phase-3-clinical-trial-of-pp-01/) [PleoPharma Announces 1st Patient Dosed in Phase 3 Clinical Trial for Cannabis Use Disorder](https://cedclinic.com/pleopharma-announces-1st-patient-dosed-in-phase-3-clinical-trial-for-cannabis-use-disorder/) Insights into the ongoing Phase 3 trial for [cannabis use disorder treatment](https://cedclinic.com/cannabis-use-disorder-treatment-pipeline-gains-momentum/) by PleoPharma. [Explore Details](https://cedclinic.com/pleopharma-announces-1st-patient-dosed-in-phase-3-clinical-trial-for-cannabis-use-disorder/) [Pleopharma To Present New Data on Cannabis Withdrawal in Patients With …](https://cedclinic.com/pleopharma-to-present-new-data-on-cannabis-withdrawal-in-patients-with/) Upcoming presentation of new data on cannabis withdrawal treatment by PleoPharma. [Learn More](https://cedclinic.com/pleopharma-to-present-new-data-on-cannabis-withdrawal-in-patients-with/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).